Drugs / EMP-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06693609 | Apr 2025 → Feb 2026 | social phobia | atai Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMP-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693609 ↗ |
| Route | Oral | “oral dosage form of EMP-01” NCT06693609 ↗ |